Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Actavis Group
Actavis Launches Ondansetron Tablets in the U.S.
July 10th, 2007
. Actavis Group (OMX: ACT), the international generic pharmaceuticals company, announced that it has launched Ondansetron Tablets in the U.S. Actavis will market the product under an agreement with Natco Pharma Limited. Distribution of the product will commence immediately. Ondansetron hydrochloride tablets, the generic equivalent of GlaxoSmithKline's Zofran(R) tablets, will be available in 4 mg and 8 mg strengths. Ondansetron hydrochloride tablets are indicated for prevention of nausea and vomiting caused by cancer chemotherapy, radiation therapy and surgery. Annual sales of Ondansetron hydrochloride tablets in the U.S. were approximately US$746...
Source: Drug Law Weekly (2007-07-10)
|
